STRO
Sutro Biopharma
NASDAQ: STRO · HEALTHCARE · BIOTECHNOLOGY
$35.39
+2.02% today
Updated 2026-04-29
Market cap
$556.51M
P/E ratio
—
P/S ratio
5.43x
EPS (TTM)
$-22.49
Dividend yield
—
52W range
$7 – $36
Volume
0.2M
Sutro Biopharma (STRO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-186.50%
Operating margin
-289.00%
ROE
-1,810.00%
ROA
-23.40%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2016 | $59.73M | $1.70M | 27.09% | 2.28% | 2.85% |
| 2017 | $51.74M | $-19.69M | -0.30% | -37.25% | -38.05% |
| 2018 | $38.42M | $-35.32M | -41.24% | -96.89% | -91.93% |
| 2019 | $42.74M | $-55.74M | 100.00% | -129.79% | -130.44% |
| 2020 | $42.72M | $-32.13M | -80.14% | -166.32% | -75.20% |
| 2021 | $61.88M | $-105.54M | 84.21% | -159.22% | -170.55% |
| 2022 | $67.77M | $-119.20M | 87.77% | -190.26% | -175.89% |
| 2023 | $153.73M | $-106.79M | 95.57% | -58.07% | -69.47% |
| 2024 | $62.04M | $-227.46M | 88.37% | -384.34% | -366.62% |
| 2025 | $102.48M | $-191.09M | 92.85% | -102.41% | -186.45% |